Rachel Cheung

Articles

Hong Kong’s Democracy Movement Receives Its Sentence

The city’s largest ever national security trial has ended with years-long jail terms handed to dozens of activists. A Wire China timeline shows how Hong Kong reached this point.

The Tipping Point

Foreign companies face a reckoning in China as the risks of staying are generating diminishing returns.

Big Pharma Doubles Down on China

Foreign pharmaceutical firms are eyeing the world’s second largest market for profit opportunities as well as innovative assets.

In 2021, after four decades of exponential growth in China’s economy, Xi Jinping revived the party slogan “common prosperity” in order to address the country’s glaring inequality. The policy priority was suddenly everywhere: in speeches, in newspapers and in schools. But now, three years later,...

Shein and Temu Face Up to a Frostier Future

The fast-growing Chinese e-commerce companies are changing tack as challenges to their cheap import models multiply.

Oriana Skylar Mastro on How China Gained Power

The political scientist explains how China has risen not just by following in the U.S.’s footsteps, but also by exploiting U.S. vulnerabilities and its own competitive advantages.

Gaining Currency

Can a central bank digital currency work? China was the first major economy to launch one and, despite several setbacks, is starting to see the digital yuan take off.

The Roadblock Facing China’s Self-Driving Vehicles

How China’s autonomous driving companies fare in foreign markets will depend on whether they can soothe concerns over how they handle data.

Yuan Yang on China’s Gender and Rural-Urban Divides

The journalist-turned-lawmaker talks about her book on four women coming of age in modern China, the end of optimism for the younger generations, and being the first Chinese-born British MP.

China’s Chip Consolidation

Beijing is weeding out bad actors in the semiconductor industry and concentrating its resources on well-established firms.

China’s Ozempic Test

Novo Nordisk, the maker of Ozempic, has enjoyed a China boom in recent years, commanding 77 percent of the market. But that kind of dominance isn’t likely to last, and Novo Nordisk’s challengers in China — both domestic and foreign — represent significant shifts in...

China’s Robot Fever

Chinese humanoid robots are working better and getting cheaper. But what are they good for?

The Wire China

Staff Writer